SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a significant price target hike from Bank of America and anticipation ahead of the upcoming earnings release. The community remains deeply divided, with bulls pointing to the firm's rapid revenue growth and infrastructure expansion, while bears continue to raise concerns regarding high valuations, aggressive capital expenditures, and potential dilution risks.

WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

Work Medical Technology Group Ltd - Ordinary Shares - Class A

Work Medical Technology Group Ltd

Work Medical Technology Group Ltd (WOK) is experiencing extreme volatility and intense community speculation following a rapid, massive decline from its overnight highs. Investors are actively debating whether the stock represents a typical Chinese pump-and-dump scheme or a high-risk opportunity for a technical rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community reacts to the REGAL trial reaching 78 of the 80 required patient events, signaling that final data and trial unblinding are imminent. Investors are actively discussing the potential for a massive short squeeze due to high short interest, while long-term shareholders remain focused on the potential of the GPS treatment to transform AML care and attract significant buyout interest.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors react to a significant partnership with Turbine-X to deploy American-made long-duration energy storage for AI-driven data centers. The community is actively debating the company's ability to scale manufacturing and execute on its growing commercial pipeline, with many traders closely monitoring high short interest and potential for a squeeze.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is facing intense volatility as shareholders react to a significant public offering priced at a discount to market levels. While some investors express frustration over the timing and dilutive nature of the raise, others are debating whether the capital influx positions the company to aggressively scale production and pursue strategic M&A within the high-demand defense drone sector.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as investors weigh hot inflation data against an aggressive corporate delegation to China, with market participants debating whether the resilience of tech-heavy sectors signals an unstoppable rally or a bubble fueled by complacency. The community is sharply divided, with bulls pointing to the strength of AI-driven capital expenditure and momentum, while bears remain focused on rising yields, elevated oil prices, and the potential for a liquidity-driven correction.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The market is showing extreme resilience and aggressive dip-buying behavior despite lingering concerns over hot producer inflation data, geopolitical tensions, and persistent oil price pressures. Investors are heavily focused on the implications of AI-driven capital expenditure and high-level corporate trade delegations to China, fueling a 'buy the dip' sentiment that continuously defies negative macro catalysts.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as investors react to a mixed earnings report that highlighted strong AI and cloud growth offset by concerns over heavy investment spending and compressed margins. While some in the community see the current price as a buying opportunity for a long-term AI play, others remain skeptical, dismissing the stock as a value trap prone to volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors react to the surprise news that CEO Jensen Huang has joined President Trumps high-stakes delegation to Beijing, sparking optimism that export restrictions on advanced AI chips could be eased. The community is sharply divided between bulls anticipating a massive breakout toward 250+ heading into earnings and bears who remain cautious due to recent hot wholesale inflation data and broader macroeconomic uncertainty.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is experiencing intense volatility as investors speculate on upcoming earnings and high-stakes contract awards. The community is sharply divided between bullish long-term supporters pointing to government contracts and space-sector growth, and bearish critics highlighting historical mission risks and speculative price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients

HeartBeam (NASDAQ: BEAT)&#160;announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting&#160;HeartBeam’s&#160;regulatory strategy [&#8230;]

HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its...

<ul><li><i>Leading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients</i></li><li><i>Opens up flagship sites across New York, Dallas, South Florida and Southern California, supporting scalable expansion of HeartBeam technology in preventive cardiology</i></li><li><i>HeartBeam continues to execute on its go-to-market strategy in high-value, direct-pay care environments</i></li></ul><p>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/"><strong>HeartBeam, Inc.</strong></a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/">Atelier Health</a>, a premier concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based Atelier Health expands HeartBeam’s commercial footprint across four targeted launch markets – New York metro, Dallas, South Florida, and Southern California – completing an initial geographic footprint to advance the Company’s scalable go-to-market strategy in concierge and preventive cardiology.</p><p>The collaboration underscores HeartBeam’s positioning within the high-value direct pay healthcare segment where adoption of innovative technologies can occur more rapidly and patients are seeking proactive cardiac insights tailored to their individual risk profiles. Through its recently announced <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.heartbeam.com/news-events/press-releases/detail/110/heartbeam-announces-first-commercial-customer-as">partnership with ClearCardio™</a>, the Company has also established its initial presence in New York metro, Dallas, and South Florida. Atelier Health extends the network to Southern California, establishing HeartBeam’s initial commercial footprint across its targeted launch markets and providing a foundation for broader national expansion.</p><p>Atelier Health, which is expanding its Beverly Hills presence with enhanced imaging capabilities and rebranding as Generational Health, offers individualized preventive and diagnostic programs supported by advanced medical protocols, specialist-level access and world-class technology. Co-founder <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/leadership/">Ram Dandillaya, MD</a>, who previously served as Clinical Chief of Cardiology at Cedars-Sinai for 8 years, and his patients previously participated in HeartBeam’s Early Access Program, gaining firsthand experience with the Company’s patented cable-free 3D ECG technology. By capturing the heart’s electrical signals in three non-coplanar dimensions and synthesizing them into a 12-lead ECG, HeartBeam enables patients to obtain high-fidelity, clinical-grade ECG data for arrhythmia assessment from the comfort of home.</p><p>“Prevention is foundational to how we care for patients, which requires access to high-quality, meaningful data beyond the clinic,” said Dr. Dandillaya. “Our model is built on delivering the highest standard of specialist care with unmatched access and precision, and HeartBeam’s technology enables a more proactive, personalized approach to evaluating cardiac symptoms in real-world settings.”</p><p>“The addition of Atelier Health reflects the growing momentum behind our commercialization strategy,” said Robert Eno, Chief Executive Officer of HeartBeam. “With flagship sites now established across our initial launch markets, we are building a strong foundation for scalable growth. We believe partnering with leading concierge and preventive cardiology practices will continue to accelerate adoption of the HeartBeam System and expand access to clinical-grade cardiac insights beyond traditional care settings.”</p><p>This partnership advances HeartBeam's commercialization strategy across the concierge and preventive cardiology segment while validating its subscription-based business model. With multiple customers now established across key geographies, HeartBeam is building a repeatable model designed to support broader national expansion.</p><p><strong>About Atelier Health</strong></p><p>Atelier Health is a concierge medical practice based in Beverly Hills, California, delivering specialist-led healthcare with a focus on personalized prevention and treatment. The practice provides patients with 24x7x365 access to expert care, offering individualized programs supported by advanced medical protocols and world-class technology. Atelier Health’s physicians are affiliated with Cedars-Sinai Medical Center, which has been recognized by U.S. News &amp; World Report as one of America’s Best Hospitals. Atelier Health’s mission is to deliver compassionate, family-centered care while providing patients access to the highest standard of U.S.-based specialty medicine. Visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://atelier90210.com/">https://atelier90210.com/</a> for more information.</p><p><strong>About HeartBeam, Inc.</strong></p><p>HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company has developed the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-Lead ECG synthesis software received FDA clearance for arrhythmia assessment in December 2025<sup>1</sup>. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.</p><p><strong>Forward-Looking Statements</strong></p><p>All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.</p><p><sup>1</sup><strong>Cleared Indications for Use</strong></p><p>The HeartBeam System with 12-Lead ECG synthesis software is FDA cleared for arrhythmia assessment. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.</p><p>MKT-143 v0</p><p>&nbsp;</p><p>View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260507972967/en/">https://www.businesswire.com/news/home/20260507972967/en/</a></p><p><strong>Media Contact:</strong><br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a></p><p><strong>Investor Relations Contact:</strong><br>Chris Tyson<br>Executive Vice President<br>MZ North America<br>Direct: 949-491-8235<br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a><br><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a></p><p>Source: HeartBeam, Inc.</p><p>Released May 7, 2026</p><div><div><div><div><div><div><div><div><div><div><div><div><i>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.</i></div></div></div></div></div></div></div></div></div></div></div></div>

HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice

HeartBeam partners with Atelier Health to expand its 3D ECG tech across key US concierge markets.

Others

HeartBeam (NASDAQ: BEAT) Expands Concierge Cardiology Footprint With Atelier Health Agreement

HeartBeam&#160;(NASDAQ: BEAT),&#160;a medical technology company focused on cardiac care solutions, announced a commercial agreement with Beverly Hills-based concierge medical practice Atelier Health, expanding the company’s launch footprint into Southern California and completing its initial targeted markets alongside New York metro, Dallas and South Florida as it advances commercialization of its cable-free 3D ECG technology for [&#8230;]

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a commercial agreement with Atelier Health, a...

HeartBeam (NASDAQ: BEAT) Tackles Heart Disease with Next-Generation ECG Solutions

Cardiovascular disease continues to be a major global health challenge, driven by aging populations, lifestyle factors and persistent gaps in early detection that continue to challenge healthcare systems. In response to these trends,&#160;HeartBeam (NASDAQ: BEAT)&#160;is developing technology aimed at improving how cardiac conditions are identified and monitored, positioning its solutions at the intersection of rising [&#8230;]

HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection [&#8230;]

HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at...

HeartBeam (NASDAQ: BEAT) Collaborates to Advance Next-Gen ECG Solutions

HeartBeam (NASDAQ: BEAT)&#160;was featured in a recent article that discussed its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move, “highlights HeartBeam’s growing focus on artificial intelligence (‘AI’)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions. The announcement [&#8230;]

HeartBeam (NASDAQ: BEAT) Closes $10M Public Offering to Advance Cardiac Technology Commercialization

HeartBeam (NASDAQ: BEAT)&#160;announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses, with the transaction completed on April 16, 2026. The offering, supported by key stakeholders including ClearCardio(TM), company leadership and institutional investors, will fund commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG [&#8230;]

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest BEAT News

BEATHeartBeam Inc